Pfizer Inc. $PFE Shares Sold by Parcion Private Wealth LLC

Parcion Private Wealth LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,145 shares of the biopharmaceutical company’s stock after selling 3,770 shares during the quarter. Parcion Private Wealth LLC’s holdings in Pfizer were worth $488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Bessemer Group Inc. raised its holdings in shares of Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in shares of Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer during the first quarter valued at approximately $8,283,000. Westbourne Investments Inc. purchased a new position in Pfizer during the first quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.5%

Shares of NYSE PFE opened at $24.72 on Thursday. The firm has a market capitalization of $140.52 billion, a PE ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.17. The firm’s 50-day moving average is $24.88 and its 200-day moving average is $24.13.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm earned $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.